Results of the study conducted by Tomita-Mitchell et al. reveal that a significant percentage of HLHS patients have rare and damaging MYH6 variants (including a novel, missense, in-frame deletion, premature stop, de novo, and compound heterozygous variants) and are predictive of poor clinical outcomes in the form of reduced transplant-free survival [31]. This evidence concerns the gene MYH6 and hypoplastic left heart syndrome.